Farris Maryanne Maunsell - May 15, 2023 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role: VP, Chief Accounting Officer
Signature: /s/ Thomas V. Powers, attorney-in-fact for Ms. Farris
Stock symbol: HAE
Transactions as of: May 15, 2023
Transactions value $: $0
Form type: 4
Date filed: 5/17/2023, 04:36 PM
Previous filing: Oct 19, 2022
Next filing: May 17, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HAE	Common Stock	Award		+630			630	May 15, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HAE	Non-qualified Stock Option (Right to Buy)	Award	$0	+1.43K		$0.00	1.43K	May 15, 2023	Common Stock	1.43K	$89.16	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F2	Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3	Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.